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EpacModerate hyperoxic exposure in preterm infants contributes to subsequent airway dysfunction and to risk of de-
veloping recurrent wheeze and asthma. The regulatory mechanisms that can contribute to hyperoxia-induced
airway dysfunction are still under investigation. Recent studies in mice show that hyperoxia increases brain-
derived neurotrophic factor (BDNF), a growth factor that increases airway smooth muscle (ASM) proliferation
and contractility. We assessed the mechanisms underlying effects of moderate hyperoxia (50% O2) on BDNF
expression and secretion in developing human ASM. Hyperoxia increased BDNF secretion, but did not alter
endogenous BDNF mRNA or intracellular protein levels. Exposure to hyperoxia signiﬁcantly increased [Ca2+]i
responses to histamine, an effect blunted by the BDNF chelator TrkB-Fc. Hyperoxia also increased ASM cAMP
levels, associatedwith reduced PDE4 activity, but did not alter protein kinase A (PKA) activity or adenylyl cyclase
mRNA levels. However, 50% O2 increased expression of Epac2, which is activated by cAMP and can regulate pro-
tein secretion. Silencing RNA studies indicated that Epac2, but not Epac1, is important for hyperoxia-induced
BDNF secretion, while PKA inhibition did not inﬂuence BDNF secretion. In turn, BDNF had autocrine effects of
enhancing ASM cAMP levels, an effect inhibited by TrkB and BDNF siRNAs. Together, these novel studies suggest
that hyperoxia canmodulate BDNF secretion, via cAMP-mediated Epac2 activation in ASM, resulting in a positive
feedback effect of BDNF-mediated elevation in cAMP levels. The potential functional role of this pathway is to
sustain BDNF secretion following hyperoxic stimulus, leading to enhanced ASM contractility and proliferation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
In spite of signiﬁcant changes in neonatal intensive care clinical
practice for respiratory support of premature infants, such as limiting
the extent of supplemental oxygen (moderate hyperoxia) andminimiz-
ing mechanical ventilation, in order to lessen incidence of lung injury
and bronchopulmonary dysplasia [1–5], the major short-term and
long-term problem for survivors of this critical period remains chronic
airway disease [6–10], manifested as wheezing, asthma, and increased
risk of respiratory infection. Indeed, regardless of other lung changes,
former preterm infants continue to be at high risk for airway hyperreac-
tivity throughout infancy and childhood [11–15], suggesting that be-
yond alveolar and vascular targets, factors such as moderate hyperoxia
affect the structure and function of the developing tracheobronchialinic, 200 First St SW, Rochester,tree. However, themechanisms bywhich hyperoxia affects the growing
airway are still under investigation.
Enhanced airway tone and reactivity involve increased broncho-
constriction mediated by greater [Ca2+]i and force responses of airway
smooth muscle (ASM) [16–19], as well as by airway remodeling and
wall thickening mediated in part by increased ASM proliferation [16,
20–22]. In this regard, an emerging theme is the role of growth factors
such as neurotrophins (nerve growth factor, brain-derived neurotrophic
factor, BDNF) that are more known for their role in the nervous system,
but are increasingly recognized to be involved in non-neuronal tissues
[23–25]. In adult airways, we and others have reported that BDNF and
its receptors (TrkB, p75NTR) are expressed in ASM [26,27], suggesting
that the airway is both source and target for BDNF, and that BDNF en-
hances ASM [Ca2+]i and contractility as well as ASM cell proliferation
[27,28]. These data suggest a prominent role for BDNF in local control of
airway structure and function. However, the role of BDNF in developing
airway is still emerging [23,29,30]. In this regard, we have previously
shown that moderate hyperoxia increases intracellular ASM BDNF, and
enhances TrkB-mediatedpro-contractile effects of BDNFonASM, suggest-
ing that BDNF is a key player in hyperoxia-induced increase of tone and
2507M.A. Thompson et al. / Biochimica et Biophysica Acta 1853 (2015) 2506–2514reactivity of developing airway. What is not known are the mechanisms
underlying regulation of BDNF by hyperoxia, and its consequences for
airway tone and reactivity in this setting.
While it is likely that BDNF generation and secretion ismodulated by
a number of factors, for endogenous BDNF to have autocrine effects, it
must be secreted. In this regard, data in neurons show that post-
transcriptionally, pro-BDNF is cleaved by proteases to form a mature
product, while secretory vesicles facilitate both pro- and mature BDNF
release [31,32]. However, in ASM, regulation of BDNF expression and
secretion are not well deﬁned. Among the several factors that may reg-
ulate BDNF at least in other cell types such as neurons, two pathways
particularly important to airway physiology are the cyclic nucleotides
cGMP [33–35] and cAMP [36–39]. Previous studies in neurons [40–42]
and endothelium [43,44] consistently show that cAMP regulates
increases in BDNF secretion. In airways, elevated levels of cAMP is
associated with bronchodilation, but limited data in adult airways
suggest that BDNF actually enhances airway [Ca2+]i and contractility.
Furthermore, limited data suggest that hyperoxia can increase cAMP,
but again hyperoxia also increases [Ca2+]i. This raises the question re-
garding the links between BDNF secretion, cAMP and [Ca2+]i regulation
in the context of hyperoxia. In the present study, we examined the role
of cAMP in regulation of BDNF in the developing airway, focusing on the
potential roles for phosphodiesterases (PDEs) and PKA-independent
guanine nucleotide exchange factor Epac [45–50], which can promote
activation of secretory proteins that modulate exocytosis [51,52].
2. Methods
2.1. Isolation of human fetal airway smooth muscle cells
The techniques have been previously described [53]. Brieﬂy, ASM
cells were enzymatically dissociated from tracheobronchial tissue of
de-identiﬁed non-viable 18–22 week gestation fetuses (Dr. Pandya or
from Novogenix Los Angeles, CA; protocols approved and considered
exempt by the Mayo Institutional Review Board and Ethics Committees
in the UK). Persistence of smooth muscle phenotype was veriﬁed by
expression of smooth muscle myosin and actin and Ca2+ regulatory
proteins, but lack of expression of E-cadherin (epithelial marker) [53,54].
2.2. Cell treatments
Fetal ASM were incubated at humidiﬁed 95% air/5% CO2 in DMEM/
F12 phenol red free medium, 10% FBS, 1% antibiotic–antimycotic (Life
Technologies, Carlsbad, CA) and grown to 80% conﬂuence prior to exper-
iments. Cells were serum starved in 0.5% FBSmedium for 24 h prior to all
studies. The next day, fresh 0.5% FBSmedia was added to plates and cells
were treated with media only, 100 μM dibutyl-cAMP (cell-permeant
cAMP analog; EMD Millipore, Billerica, MA), 10 μM Roﬂumilast (PDE4
inhibitor; Cayman Chemical, Ann Arbor, MI), 0.5 μMKT5720 (PKA inhib-
itor; EMDMillipore), or 10 μM8-CPT-2-O-Me-cAMP-AM (Epac-selective
cAMP analog; Tocris Bioscience, U.K.) for 30 min and then exposed to
room air (21% O2) or hyperoxia (50% O2) for 8, 12, 24, or 48 h. Oxygen
levels were monitored using a MiniOx 3000 oxygen monitor (MSA
Medical Products, Pittsburgh, PA). Media or cell lysates were collected
and stored at−80 °C until analyses.Table 1
Quantitative real time PCR primer sequences.
Gene Forward primer
Adenylyl cyclase 3 TTCAACCCTGGGCTCAATGG
Adenylyl cyclase 4 CAATCCGGGTTTGAGGGAGG
Adenylyl cyclase 6 TAGCTTGTCAGTGGGAAGTGC
Adenylyl cyclase 7 GGGACGCTCTGCACTATCTC
Adenylyl cyclase 9 CATAAAAACAGCACCAAGGCT
BDNF ATACTTTGGTTGCATGAAGGCT
GAPDH AAGGTGAAGGTCGGAGTCAAC2.3. [Ca2+]i imaging
In gas permeable 24 well plates (Coy Laboratories), fetal ASM cells
were incubated with 5 μM Fluo-4 AM for 60 min at room temperature,
washed, and cells imaged (20 cells/ﬁeld) in real time using a Nikon
Eclipse TE2000-U ﬂuorescent microscope (20× Plan Fluor objective
lens) and imaging system software (MetaFluor; Universal Imaging,
Downingtown, PA). Baseline [Ca2+]i was established for 20s followed
by addition of histamine (10 μM) and responses recorded for 2 min.
Responses were calculated by comparing the ratio of peak ﬂuorescence
to the average baseline ﬂuorescence.
2.4. Transfection with siRNAs
Fetal ASM cells were transfected with 20 nM (ﬁnal concentration)
siRNA against EPAC1, EPAC2, BDNF or TrkB (GE Dharmacon), via
manufacturer protocols, under serum- and antibiotic-free conditions
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for 24 h followed
by 48 h normoxia or hyperoxia exposure in serum-free medium.
Treatment with Lipofectamine alone and transfection with scrambled
(non-targeting RNA) served as controls.
2.5. ELISA
BDNF levelsweremeasured inmedia using human BDNFQuantikine
ELISA kit (R&D Systems, Minneapolis, MN) following manufacturer's
protocol. Absorbance at 450 nm was measured using a Flexstation3
plate reader (Molecular Devices, Sunnyvale, CA). Comparison to a stan-
dard curve was used to determine BDNF concentration in samples.
2.6. Measurement of cAMP levels
Cells were treated in the presence of 10 μM IBMX (phosphodiester-
ase inhibitor) with media only, 10 nM BDNF, or 1 μg/mL TrkB-Fc during
exposure to 21% O2 or 50% O2 for 48 h. Following exposures, 5% (ﬁnal
concentration) trichloroacetic acid (TCA) was immediately added to
media and subsequently extracted by adding 5× volume of water satu-
rated ether tomedia. Sampleswere vortexed, layers allowed to separate
and the top layer (ether layer) was removed with the process repeated
twice more for a total of three extractions. Cyclic AMP levels in media
were measured by ELISA following the manufacturer's protocol
(Biomedical Technologies, Stoughton, MA) for acetylated samples.
Absorbance at 410 nm was measured and cAMP concentration in
media determined by comparison to a standard curve.
2.7. Phosphodiesterase activity
PDE4 activity was measured using a cyclic nucleotide phosphodies-
terase activity kit (Enzo Life Sciences, Farmingdale, NY) according to
the manufacturer's protocol. Brieﬂy, fetal ASM cells were exposed to
21% O2 or 50% O2 for 48 h and harvested using the supplied PDE assay
buffer containing 10 mM Tris–HCl, pH 7.4. Extracts containing 2.5 μg
protein were then incubated with 3′, 5′-cAMP and 5′-nucleotidase
(200 μM and 50 kU ﬁnal concentrations respectively) in the presence
or absence of a PDE4 inhibitor, 10 μM Roﬂumilast, for 60 min at 30 °C.Reverse primer
TCTACGTGGCGGGAGAAGTA
TGGCAATCCCGTCTCCTTTTT
ACATGTTGCTGGTAGGGAAGG
ACTTGGAAAGGCATCAGGGG
AGTCTGACTGTTGGTGAGCTT
GCCC CGAACTTTCTGGTCCTCATCC AACAG
GGATT AAGGTGAAGGTCGGAGTCAACGGATT
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and, after 30 min for color development, OD determined at 620 nm.
PDE4 activity was determined by comparing the amount of phosphateFig. 1.Effect of 50%O2 exposure onBDNF expression and secretion. (A) Cellswere exposed
to 21%O2 or 50%O2 for 8 h, 24 h or 48 h. Exposure to 50%O2 increasedBDNF secretion after
24 and 48 h of exposure. (B) BDNF mRNA levels were not altered at 8 and 48 h, (C) and
intracellular BDNF expression was also unchanged after exposure to 50% O2 for 48 h.
Message RNA levels are presented as fold change relative to control. Data are presented
as mean ± SE, n = at least 3 samples, p b 0.05. * indicates signiﬁcant difference from
21% O2 at the respective time point.released from samples incubated with or without Roﬂumilast and
normalized to the amount of protein in cell lysate.
2.8. Protein kinase A activity
Cells were untreated or incubated with 100 μM dibutyl-cAMP
(db-cAMP) during exposure to 21% O2 or 50% O2 for 48 h. Cell lysates
were collected and PKA activity was measured using a solid phase
ELISA-based kit (Enzo Life Sciences) following the manufacturer's
protocol. Absorbance at 450 nm was measured. To calculate relative
PKA activity, OD values were divided by protein concentrations. Values
were normalized to untreated and 21% O2 control. To conﬁrm the inhib-
itory effect of KT5720, fetal ASM cells were incubated with 10 μM
isoproterenol or 100 μM 8-Br-cAMP for 30 min in the presence or
absence of 0.5 μM KT5720. Cell lysates collected and probed for PKA
activity to conﬁrm effectiveness of inhibitor (data not shown).
2.9. Real time PCR
RNA was isolated using RNeasy Mini kit (Qiagen, Valencia, CA) and
complementary DNA was synthesized using a reverse transcription kit
(Roche, Indianapolis, IN). For qRT-PCR reactions, cDNA, forward and
reverse primers, and SYBR green master mix (Roche), were ampliﬁed
with using LC480 Light Cycler (Applied Biosystems, Carlsbad, CA) for
60 cycles. Primer sequences are summarized in Table 1. The housekeep-
ing gene, GAPDH, was used to normalize Ct values.Fig. 2. Role of BDNF in [Ca2+]i response following 50% O2 exposure. Fetal ASM in media
only or TrkB-Fc (BDNF chelator) were exposed to 21% O2 or 50% O2 for 48 h. Cells were
then loaded with Fluo-4 and stimulated with 10 μM histamine. [Ca2+]i response was
greater in cells exposed to 50% O2 than 21% O2-exposed cells while cells treated with
TrkB-Fc during 50% O2 exposure blunted the peak [Ca2+]i response. Data are presented
as mean ± SE, n = 3 samples, p b 0.05. * indicates signiﬁcant difference from 21% O2. #
indicates signiﬁcant difference from 50% O2.
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Cells were harvested using standard techniques (cell lysis buffer
containing protease inhibitors). Protein was separated by SDS PAGE
using a 4–15% Tris–HCl gel and transferred to nitrocellulosemembranes
using a Bio-Rad Trans-Blot Turbo rapid transfer system (Bio-Rad,
Hercules, CA). Primary antibodies used include BDNF, Epac1, Epac2
(Abcam, Cambridge, MA), and β-actin (Sigma-Aldrich, St. Louis, MO).
Membranes were imaged on a Li-Cor OdysseyXL system and densitom-
etry was quantiﬁed with Image Studio software. Protein blots were
normalized to β-actin.
2.11. Statistics
Fetal ASM isolated from at least 3 different fetal lung samples, with
multiple repetitions for each sample for all experiments. Data were
analyzed by unpaired t-test and presented as mean ± standard error
(SE). Statistical signiﬁcance is indicated as p b 0.05.
3. Results
3.1. Effect of hyperoxia on BDNF expression and secretion
ELISA of fetal ASM showed a signiﬁcant increase in BDNF secretion
(pg/mL) from 50% O2 exposed cells at 24 and 48 h (but not 12 h) com-
pared to room air (p b 0.05; Fig. 1A). To determine if 50% O2 increases
BDNF transcription, RNAwas isolated from fetal ASM for qRT-PCR anal-
ysis following 8 and 48 h of 21% O2 or 50% O2 exposure. There was no
difference observed in BDNF mRNA expression between time pointsFig. 3. Effect of 50% O2 on cAMP levels and PDE4 activity. (A) Cells were exposed to 21% O2 or 5
(B) Compared to control cells, 50% O2 exposure led to reduced PDE4 activity in cell lysates. (C) C
48 h. While db-cAMP increased PKA activity, exposure to 21% O2 or 50% O2 for did not signiﬁca
altered in cells exposed to 50% O2 for 48 h. Data are presented as mean ± SE, n = 3–4 sample(Fig. 1B). Additionally, intracellular BDNF expression at 48 h was
assessed and found not to be altered (Fig. 1C).
3.2. Effect of hyperoxia on [Ca2+]i responses to histamine
In Fluo-4 loaded fetal ASM cells 48 h exposure to moderate
hyperoxia signiﬁcantly increased the amplitude of [Ca2+]i responses
to 10 μM histamine compared to normoxic controls. Incubation with
the chimeric BDNF chelator TrkB-Fc (1 μg/mL) signiﬁcantly reduced
the peak histamine responses in fetal ASM exposed to both normoxia
and moderate hyperoxia (p b 0.05; Fig. 2).
3.3. Effect of cAMP on hyperoxia-induced BDNF secretion
Fetal ASMwere exposed to 50%O2 for 48 h followed bymeasurement
of cyclic AMP levels via ELISA. Compared to normoxic control cells, 50%
O2 signiﬁcantly increased cAMP levels (p b 0.05; Fig. 3A). Conversely,
cells exposed to 50%O2 for 48 h show signiﬁcantly decreased PDE4 activ-
ity (p b 0.05; Fig. 3B). Fetal ASM treated with the cell-permeant cAMP
analog db-cAMP showed a signiﬁcant increase in PKA activity, while
50% O2 exposed cells did not have enhanced PKA activity (Fig. 3C).
Expression of AC isoforms (3, 4, 5, 7, and 9) was not changed in cells
exposed to 50% O2 (Fig. 3D).
Fetal ASM incubated with PDE4 inhibitor Roﬂumilast for 48 h
showed signiﬁcant increase in BNDF secretion in normoxia-exposed
cells, compared to untreated controls (p b 0.05; Fig. 4A); however, no
such difference was observed in Roﬂumilast-treated fetal ASM exposed
to hyperoxia. Consistently, fetal ASM incubatedwith Roﬂumilast show a
signiﬁcant increase in cAMP levels in normoxia compared to untreated0% O2 for 48 h. Cyclic AMP levels were increased in fetal ASM exposed to 50% O2 after 48 h.
ells were treatedwith control or dibutyryl-cAMP and then exposed to 21%O2 or 50% O2 for
ntly change PKA activity. (D) Adenylyl cyclase isoform mRNA expression levels were not
s, p b 0.05. * indicates signiﬁcant difference from 21% O2.
Fig. 5.Effect of cAMP analog and PKA inhibitor onBDNF secretion. Fetal ASMwere exposed
to 21% O2 or 50% O2 for 48 h. Dibutyryl-cAMP (cAMP analog) increased BDNF secretion in
21% O2-exposed cells, while KT5270 (PKA inhibitor), did not alter 50% O2-induced BDNF
secretion after 48 h. Data are presented asmean± SE, n= 3 samples, p b 0.05. * indicates
signiﬁcant difference from 21% O2.
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no difference in cAMP levels was observed in Roﬂumilast-treated cells.
To determine the contribution of cAMP to BDNF secretion, cells were
treated with db-cAMP in both 21% O2 and 50% O2. BDNF secretion was
signiﬁcantly increased in cells treated with db-cAMP in both the 21%
O2 and 50% O2 exposed groups (Fig. 5). Since cAMP effects can be medi-
ated through PKA,we compared secretion of BDNF in fetal ASM exposed
to 21% O2 and 50% O2 in the absence vs. the presence of KT5270, a PKA
inhibitor. In the presence of KT5270, 50% O2 continued to stimulate
BDNF secretion (p b 0.05; Fig. 5).
3.4. Role of Epac proteins in hyperoxia-induced BDNF secretion
Cyclic AMP can facilitate protein secretion through activation of
Epac1 and Epac2. Since PKA activity did not appear to play a role in
BDNF secretion during 50% O2 exposure, we alternatively hypothesized
that Epac1 and/or Epac2 mediate BDNF secretion. Exposure to 10 μM 8-
CPT-2-O-Me-cAMP-AM, an Epac1 and Epac2 activator, for 48 h resulted
in signiﬁcant increase of BNDF secretion at normoxia. However, no
change in BDNF secretion was observed in 8-CPT-2-O-Me-cAMP-AMFig. 4. Role of PDE4 in modulating BDNF secretion. (A) Fetal ASM were incubated in the
presence or absence of Roﬂumilast and exposed to 21% or 50% O2 for 48 h and media
assayed for BDNF. Roﬂumilast signiﬁcantly increased BDNF secretion under normoxic con-
ditions but not during hyperoxia exposure. (B) Cells treatedwith Roﬂumilast and exposed
to normoxia and hyperoxia for 48 hwere analyzed for cAMP levels. Signiﬁcant increases in
cAMP levels are observed in cells treated with Roﬂumilast in 21% O2; however, no change
is seen in Roﬂumilast treated cells compared to controlswhen exposed to 50% O2. Data are
presented as mean ± SE, n = 3 samples, p b 0.05. * indicates signiﬁcant difference from
21% O2.stimulated cells exposed to 50% O2 (Fig. 6A). To elucidate the role of
Epac1 and Epac2 on BDNF secretion, we utilized Epac1 and Epac2
siRNA in cells exposed to 21% O2 or 50% O2 for 48 h. Although siRNA
knockdown of Epac1 expression did not alter 50% O2-induced BDNF se-
cretion, cells treated with Epac2 siRNA showed signiﬁcantly decreased
BDNF secretion with 50% O2 exposure (p b 0.05; Fig. 6B). Compared to
21% O2 exposed cells, 50% O2 increased expression of Epac1 and Epac2
(p b 0.05; Fig. 6C).
3.5. Effect of BDNF on cAMP
In neurons, BDNF can regulate cAMP levels, thus resulting in a feed-
forwardmechanism. We investigated the role of BDNF and its receptor,
TrkB, on cAMP levels. Cells were treated with exogenous BDNF or with
the chimeric compound TrkB-Fc, which chelates extracellular BDNF,
during 21% O2 or 50% O2 exposure for 48 h. Cyclic AMP levels were
signiﬁcantly increased in cells exposed to BDNF, and 50% O2 enhanced
such effects of BDNF on cAMP (p b 0.05; Fig. 7A). Furthermore, cells
transfected with siRNA targeting BNDF or TrKB signiﬁcantly reduced
cAMP levels in cells exposed to 21% O2 or 50% O2 (p b 0.05; Fig. 7B).
Interestingly, TrkB-Fc did not prevent increases in cAMP levels during
50% O2 exposure (Fig. 7).
4. Discussion
Recent studies implicate BDNF as a contributor to airway
hypercontractility and remodeling, which are hallmark features of
airway diseases. Previously, we have demonstrated that human ASM
express BDNF and its receptors, TrkB and p75NTR. Via autocrine or para-
crine activation of TrkB, BDNF can regulate human ASM proliferation
and Ca2+ regulatory mechanisms which are both key for dysfunction
in airway disease [28,55–57]. However, there is currently limited data
on the source and role of BDNF in the developing airway or its functional
signiﬁcance. In the present study, we show that human fetal ASM
expresses and secretes BDNF, with increased secretion in the presence
of moderate hyperoxia. Such secreted BDNF contributes to hyperoxia-
enhanced [Ca2+]i responses to agonist: effects blunted by TrkB-Fc, a
chimeric peptide chelator. In this regard, [Ca2+]i per se might be con-
tributory to BDNF secretion and its effects, as suggested by previous
studies in adult ASM showing that on the one hand, hyperoxia enhances
[Ca2+]I, while conversely BDNF secretion is blunted by [Ca2+]i chelation
[57]. The present study now demonstrates the importance of cAMP in
the link between hyperoxia and BDNF in the context of [Ca2+]i. Together,
these ﬁndings are relevant to the use of hyperoxia in the neonatal ICU for
premature infants, and suggests the potential for BDNF to then have
autocrine/paracrine effects on the developing airway (Fig. 8).
Fig. 6. Role of Epac1 and Epac2 in BDNF secretion. (A) Fetal ASM cells were exposed to 21% O2 or 50% O2 for 48 h in the presence or absence of 8-CPT-2-O-Me-cAMP-AM and supernatants
assayed for BDNF secretion via ELISA. Levels of BDNF were increased in the presence of Epac stimulation in 21% O2, but not during 50% O2 exposure. (B) BDNF secretion was decreased in
50% O2 exposed cells transfectedwith Epac2 siRNA, but not Epac1 siRNA. (C) Cells were treatedwith control, Epac1 or Epac2 siRNA during exposure to 21% O2 or 50% O2 for 48 h. Exposure
to 50% O2 increased expression of Epac2. Data are presented asmean± SE. p b 0.05. * indicates signiﬁcant effect of Epac siRNA; # indicates signiﬁcant difference from 21% O2+ scrambled
siRNA.
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lar functions including exocytosis, cell proliferation andmuscle contrac-
tion. In the present study, exposure to 50% O2 resulted in increased
cAMP levels in fetal ASM. A number of mechanisms may contribute to
hyperoxia-induced changes in cAMP including adenylyl cyclase and
the phosphodiesterases (PDEs). In adult ASM, PDE4 is a key regulator
of cAMP levels [58] and reduction in its activity can lead to increased ac-
tivation of cAMP-mediated pathways [59]. However, there is currently
very little information on these mechanisms in the developing airway.
In human fetal ASM, we found that exposure to hyperoxia decreased
PDE4 activity, a ﬁnding in contrast to data in alveoli of mouse and rat
pups [60,61] whichmay reﬂect differential hyperoxia effects on airways
vs. lung parenchyma, species differences, as well as differences in oxy-
gen concentration and duration. While we did not speciﬁcally examine
the mechanisms by which hyperoxia affects PDE4, oxidative stress is a
likely pathway. For example, previous studies on endothelial progenitor
cells (EPCs) report a dramatic decrease in PDE4B and PDE4C mRNA
levels (but not PDE5) in response to oxidative stress [62], resulting in
compromised angiogenic potential. Our studies are the ﬁrst to establish
hyperoxia-induced changes in PDE4 in fetal ASM, and the data are
consistent with hyperoxia-induced increased cAMP. Additionally,
there is little data on the effect of hyperoxia on adenylyl cyclase (AC),
the enzyme which catalyzes formation of cAMP. Previous studies have
suggested that oxidative stress does not alter the expression of AC6 in
murine EPCs [62], but little is known about its effect on the developing
airway. Given the range of AC isotypes, a thorough investigation into
the role of the AC pathway was beyond the scope of this particularstudy. However, mRNA screening found AC3, 4, 6, 7 and 9 in fetal
ASM. Importantly, and somewhat surprisingly, none of these mRNAs
were altered by moderate hyperoxia. Pilot studies using the AC inhibi-
tor, SQ22536 showed only modest decrease in cAMP in the presence
of 50% O2 suggesting that much of the hyperoxia effect on cAMP may
involve PDEs or other non-AC mechanisms.
We also assessed the interaction between cAMP and BDNF during
hyperoxia exposure. Treatment with exogenous cAMP increased BDNF
secretion during 21% O2 and 50% O2 exposure. While BDNF increased
cAMP levels in 21% O2 exposed cells, 50% O2 exposure and BDNF treat-
ment synergistically increased cAMP levels. However, chelation of
secreted BDNF did not alter increased cAMP levels during 50% O2 expo-
sure. Knockdown of BDNF and TrkB expression, using siRNA, reduced
cAMP levels while cells were exposed to hyperoxia. Overall, these data
demonstrate that secreted BDNF does have an autocrine effect on
cAMP levels per se during exposure to hyperoxia.
The role of cAMP in ASM is complex and is relevant to multiple
mechanisms in the airway, most notably for mediating ASM relaxation
via β-agonists. PKA is activated in response to increases in cAMP levels
and can inhibit multiple pro-contractile mechanisms within ASM.
Although exposure to 50% O2 increased cAMP levels, we found that
PKA activity was not altered, a ﬁnding similar to previous studies in
neonatal and adult rats which reported a lack of PKA activation in the
presence of hyperoxia therefore suggesting an alternate target of
cAMP [57,58]. Additionally, pharmacological inhibition of PKA activity
did not alter 50%O2-induced BDNF secretion. Previous studies in neona-
tal mouse cardiac ﬁbroblasts have found that isoproterenol-stimulated
Fig. 7. Effect of BDNF and TrkB on cAMP levels. (A) Fetal ASM were untreated or treated
with BDNF or TrkB-Fc during exposure to 21% O2 or 50% O2 for 48 h. BDNF increased
cAMP levels while the BDNF chelator, TrkB-Fc, reduced 50% O2-induced cAMP levels.
(B) Cells transfected with siRNA against BDNF and TrkB show a signiﬁcant reduction in
cAMP levels. Data are presented as mean ± SE, n = 3, p b 0.05. * indicates signiﬁcant dif-
ference from 21% O2; # indicates signiﬁcant difference from 50% O2.
Fig. 8. Mechanism of BDNF secretion in fetal ASM. Exposure to moderate hyperoxia
increases BDNF secretion, but not mRNA or protein expression, in developing ASM.
Hyperoxia also increased cAMP levelswhichmay be due, in part, to reduced phosphodies-
terase 4 (PDE4) activity. The effect of hyperoxia on BDNF is independent of PKA activation.
However, our data suggests that BDNF secretion is mediated through Epac2 to modulate
protein exocytosis. In addition to hyperoxia, BDNF also increased cAMP levels which
suggest that, possibly through its receptor TrkB, secreted BDNF could enhance the
cAMP-Epac2 pathway.
2512 M.A. Thompson et al. / Biochimica et Biophysica Acta 1853 (2015) 2506–2514release of IL-6 can be regulated independent of PKA activation indicat-
ing a novel mechanism for modulating secretion [63]. Based on these
data, we speculate that cAMP facilitates BDNF secretion through a
PKA-independent mechanism.
Epac1and Epac2 are proteins thatwere recently identiﬁed as guanine
exchange factors whose activity are cAMP dependent [64]. Epac activity
leads to activation of Ras-like small GTPases, including Rap1 [64]. Epac1
and Epac2 mRNA expression were reported in the neonatal mouse lung
among other tissues such as the heart and brain [65]. At 3 weeks of age,
their expression in the mouse lung increased compared to fetal lung
expression [65], however to date the expression patterns in the human
lung have not been reported. Although transcriptional regulation of
Epac expression remains undeﬁned, recent studies showed that TGFβ
decreases Epac1 expression in cardiac and lung ﬁbroblasts [66]. The
effects of hyperoxia on Epac expression has not been explored in the
context of the developing lung. Given the differential expression of
Epacs in the lung during the neonatal period and the effects of hyperoxia
on Epac2, future studies should investigate Epacs during hyperoxia
exposure. Our study suggests that Epacs in ASM may be important for
signaling in the developing airway, and in development of neonatal
airway diseases, e.g. via secretion of growth factors such as BDNF.
Epac2 and Rap1 regulate insulin secretion in pancreatic β cells [67].
Thus, we hypothesized that Epac1 and/or Epac2 may be involved in
BDNF secretion stimulated by exposure 50% O2. Expression of Epac2,
but not Epac1, was increased upon exposure to 50% O2. Subsequently,
we used siRNA knockdown studies to determine if Epac1 and/or Epac2
were involved in BDNF secretion. Our studies demonstrate that Epac2
was involved in BDNF secretion during 50% O2 exposure. Recent studies
demonstrate that Epac1 and Epac2 regulate bradykinin-induced IL-8
secretion and relaxation mechanisms in adult ASM [68,69]. However,
Epacsmay not be involved in ASM relaxationmediated by isoproterenol,
whose effects were demonstrated to be mediated through PKA-
dependent pathways [70]. These recent studies suggest that there may
be differential effects of cAMP and Epac depending on the stimulus.
Cyclic AMP compartmentalization is another important factor that
could inﬂuence the effects of hyperoxia on BDNF secretion. A-kinase
Anchoring proteins (AKAP) contribute to regulation of cAMP by modu-
lating formation of complexes which include PDE4 and PKA [71]. In
human ASM, AKAP has been demonstrated to regulate intracellular
cAMP localization and modulate β2-adrenergic receptor signaling [72].
Epacs can also be part of the AKAP complex, recent studies showed
co-localization among Epac1, AKAP, PDE4, and PKA [73], suggesting
that Epac could potentially be part of an AKAP-regulated complex in
fetal ASM. However, the effects of hyperoxia on the formation of this
complex remain unknown. We speculate that exposure to hyperoxia
could have an as of yet undeﬁned effect on cAMPcompartmentalization,
which potentially could mediate Epac vs PKA activation.
Regarding developing ASM, modulation of Epac2 expression and
BDNF secretion by moderate hyperoxia has implications for airway
development as well as airway remodeling. These data identiﬁes a
novel role for Epac2 in protein release by ASM and set the basis for
future investigations on altered airway function/structure observed in
former preterm infants.
Transparency document
The Transparency document associated with this article can be
found, in the online version.
Acknowledgments
The study was supported by grants from the National Institutes of
Health (T32 HL105355 (Britt), F32 HL123075 (Britt), R01 HL056470
(Prakash, Martin), and R01 HL088029 (Prakash)) and the Department
of Anesthesiology, Mayo Clinic (Prakash, Pabelick).
2513M.A. Thompson et al. / Biochimica et Biophysica Acta 1853 (2015) 2506–2514References
[1] M.C. Walsh, A.M. Hibbs, C.R. Martin, A. Cnaan, R.L. Keller, E. Vittinghoff, R.J. Martin,
W.E. Truog, P.L. Ballard, A. Zadell, S.R. Wadlinger, C.E. Coburn, R.A. Ballard, Two-
year neurodevelopmental outcomes of ventilated preterm infants treated with
inhaled nitric oxide, J. Pediatr. 156 (2010) (556-561 e551).
[2] A.H. Jobe, The new bronchopulmonary dysplasia, Curr. Opin. Pediatr. 23 (2011)
167–172.
[3] D. Hayes Jr., D.J. Feola, B.S. Murphy, L.A. Shook, H.O. Ballard, Pathogenesis of
bronchopulmonary dysplasia, Respiration 79 (2010) 425–436.
[4] S.H. Abman, The dysmorphic pulmonary circulation in bronchopulmonary
dysplasia: a growing story, Am. J. Respir. Crit. Care Med. 178 (2008) 114–115.
[5] P.R. Chess, C.T. D'Angio, G.S. Pryhuber, W.M. Maniscalco, Pathogenesis of
bronchopulmonary dysplasia, Semin. Perinatol. 30 (2006) 171–178.
[6] P. Kwinta, J.J. Pietrzyk, Preterm birth and respiratory disease in later life, Expert Rev.
Respir. Med. 4 (2010) 593–604.
[7] L.W. Doyle, P.J. Anderson, Pulmonary and neurological follow-up of extremely
preterm infants, Neonatology 97 (2010) 388–394.
[8] R. Kumar, Prenatal factors and the development of asthma, Curr. Opin. Pediatr. 20
(2008) 682–687.
[9] D. Holditch-Davis, P. Merrill, T. Schwartz, M. Scher, Predictors of wheezing in
prematurely born children, J. Obstet. Gynecol. Neonatal. Nurs. 37 (2008)
262–273.
[10] A.M. Hibbs, M.C. Walsh, R.J. Martin, W.E. Truog, S.A. Lorch, E. Alessandrini, A. Cnaan,
L. Palermo, S.R. Wadlinger, C.E. Coburn, P.L. Ballard, R.A. Ballard, One-year respirato-
ry outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic
Lung Disease trial, J. Pediatr. 153 (2008) 525–529.
[11] R.B. Klein, B.W. Huggins, Chronic bronchitis in children, Semin. Respir. Infect. 9
(1994) 13–22.
[12] C.P. Speer, M. Silverman, Issues relating to children born prematurely, Eur. Respir. J.
27 (1998) 13s–16s.
[13] A. Greenough, Long-term pulmonary outcome in the preterm infant, Neonatology
93 (2008) 324–327.
[14] D.K. Ng, W.Y. Lau, S.L. Lee, Pulmonary sequelae in long-term survivors of
bronchopulmonary dysplasia, Pediatr. Int. 42 (2000) 603–607.
[15] A.A. Colin, C. McEvoy, R.G. Castile, Respiratory morbidity and lung function in
preterm infants of 32 to 36 weeks' gestational age, Pediatrics 126 (2010) 115–128.
[16] K. Mahn, O.O. Ojo, G. Chadwick, P.I. Aaronson, J.P. Ward, T.H. Lee, Ca(2+) homeosta-
sis and structural and functional remodelling of airway smooth muscle in asthma,
Thorax 65 (2010) 547–552.
[17] Y. Amrani, R.A. Panettieri Jr., Cytokines induce airway smooth muscle cell
hyperresponsiveness to contractile agonists, Thorax 53 (1998) 713–716.
[18] Y. Amrani, R.A. Panettieri Jr., Modulation of calcium homeostasis as a mechanism for
altering smooth muscle responsiveness in asthma, Curr. Opin. Allergy Clin.
Immunol. 2 (2002) 39–45.
[19] Y. Chiba, M. Misawa, The role of RhoA-mediated Ca2+ sensitization of bronchial
smooth muscle contraction in airway hyperresponsiveness, J. Smooth Muscle Res.
40 (2004) 155–167.
[20] J.K. Bentley, M.B. Hershenson, Airway smooth muscle growth in asthma: prolifera-
tion, hypertrophy, and migration, Proc. Am. Thorac. Soc. 5 (2008) 89–96.
[21] B.G. Dekkers, H. Maarsingh, H. Meurs, R. Gosens, Airway structural components
drive airway smooth muscle remodeling in asthma, Proc. Am. Thorac. Soc. 6
(2009) 683–692.
[22] S. Siddiqui, J.G. Martin, Structural aspects of airway remodeling in asthma, Curr.
Allergy Asthma Rep. 8 (2008) 540–547.
[23] M. Scuri, L. Samsell, G. Piedimonte, The role of neurotrophins in inﬂammation and
allergy, Inﬂamm. Allergy Drug Targets 9 (2010) 173–180.
[24] Y. Prakash, M.A. Thompson, L. Meuchel, C.M. Pabelick, C.B. Mantilla, S. Zaidi, R.J.
Martin, Neurotrophins in lung health and disease, Expert. Rev. Respir. Med. 4
(2010) 395–411.
[25] Q. Yao, S.I. Zaidi, M.A. Haxhiu, R.J. Martin, Neonatal lung and airway injury: a role for
neurotrophins, Semin. Perinatol. 30 (2006) 156–162.
[26] L. Meuchel, E. Townsend, M. Thompson, S. Cassivi, Y. Prakash, Neurotrophins
Produce Nitric Oxide in Human Airway Epithelium, American Thoracic Society
International Conf, San Diego CA, 2010.
[27] Y.S. Prakash, A. Iyanoye, B. Ay, C.B. Mantilla, C.M. Pabelick, Neurotrophin effects on
intracellular Ca2+ and force in airway smooth muscle, Am. J. Physiol. Lung Cell.
Mol. Physiol. 291 (2006) L447–L456.
[28] B. Aravamudan, M. Thompson, C. Pabelick, Y.S. Prakash, Brain-derived neurotrophic
factor induces proliferation of human airway smooth muscle cells, J. Cell. Mol. Med.
16 (2012) 812–823.
[29] Q. Yao, M.A. Haxhiu, S.I. Zaidi, S. Liu, A. Jafri, R.J. Martin, Hyperoxia enhances brain-
derived neurotrophic factor and tyrosine kinase B receptor expression in
peribronchial smooth muscle of neonatal rats, Am. J. Physiol. Lung Cell. Mol. Physiol.
289 (2005) L307–L314.
[30] G. Piedimonte, Contribution of neuroimmune mechanisms to airway inﬂammation
and remodeling during and after respiratory syncytial virus infection, Pediatr. Infect.
Dis. J. 22 (2003) (S66-74; discussion S74-65).
[31] S.J. Mowla, H.F. Farhadi, S. Pareek, J.K. Atwal, S.J. Morris, N.G. Seidah, R.A. Murphy,
Biosynthesis and post-translational processing of the precursor to brain-derived
neurotrophic factor, J. Biol. Chem. 276 (2001) 12660–12666.
[32] V. Lessmann, T. Brigadski, Mechanisms, locations, and kinetics of synaptic BDNF
secretion: an update, Neurosci. Res. 65 (2009) 11–22.
[33] M. Canossa, E. Giordano, S. Cappello, C. Guarnieri, S. Ferri, Nitric oxide down-
regulates brain-derived neurotrophic factor secretion in cultured hippocampal
neurons, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3282–3287.[34] C.R. Furini, J.I. Rossato, L.L. Bitencourt, J.H. Medina, I. Izquierdo, M. Cammarota, Beta-
adrenergic receptors link NO/sGC/PKG signaling to BDNF expression during the
consolidation of object recognition long-term memory, Hippocampus 20 (2010)
672–683.
[35] H.Y. Hsieh, C.L. Robertson, A. Vermehren-Schmaedick, A. Balkowiec, Nitric oxide
regulates BDNF release from nodose ganglion neurons in a pattern-dependent and
cGMP-independent manner, J. Neurosci. Res. 88 (2010) 1285–1297.
[36] Y. Dwivedi, G.N. Pandey, Adenylyl cyclase-cyclic AMP signaling in mood disorders:
role of the crucial phosphorylating enzyme protein kinase A, Neuropsychiatr. Dis.
Treat. 4 (2008) 161–176.
[37] D. Tardito, J. Perez, E. Tiraboschi, L. Musazzi, G. Racagni, M. Popoli, Signaling path-
ways regulating gene expression, neuroplasticity, and neurotrophic mechanisms
in the action of antidepressants: a critical overview, Pharmacol. Rev. 58 (2006)
115–134.
[38] A.C. Conti, J.F. Cryan, A. Dalvi, I. Lucki, J.A. Blendy, cAMP response element-binding
protein is essential for the upregulation of brain-derived neurotrophic factor
transcription, but not the behavioral or endocrine responses to antidepressant
drugs, J. Neurosci. 22 (2002) 3262–3268.
[39] R. Deogracias, G. Espliguero, T. Iglesias, A. Rodriguez-Pena, Expression of the
neurotrophin receptor trkB is regulated by the cAMP/CREB pathway in neurons,
Mol. Cell. Neurosci. 26 (2004) 470–480.
[40] D.F. Condorelli, P. Dell'Albani, G. Mudo, T. Timmusk, N. Belluardo, Expression of
neurotrophins and their receptors in primary astroglial cultures: induction by cyclic
AMP-elevating agents, J. Neurochem. 63 (1994) 509–516.
[41] S.J. Jeon, S.Y. Rhee, J.E. Seo, H.R. Bak, S.H. Lee, J.H. Ryu, J.H. Cheong, C.Y. Shin, G.H.
Kim, Y.S. Lee, K.H. Ko, Oroxylin A increases BDNF production by activation of
MAPK-CREB pathway in rat primary cortical neuronal culture, Neurosci. Res. 69
(2011) 214–222.
[42] M. Yamamoto, G. Sobue, M. Li, Y. Arakawa, T. Mitsuma, K. Kimata, Nerve growth
factor (NGF), brain-derived neurotrophic factor (BDNF) and low-afﬁnity nerve
growth factor receptor (LNGFR) mRNA levels in cultured rat Schwann cells;
differential time- and dose-dependent regulation by cAMP, Neurosci. Lett. 152
(1993) 37–40.
[43] T. Nakahashi, H. Fujimura, C.A. Altar, J. Li, J. Kambayashi, N.N. Tandon, B. Sun,
Vascular endothelial cells synthesize and secrete brain-derived neurotrophic factor,
FEBS Lett. 470 (2000) 113–117.
[44] A. Caporali, C. Emanueli, Cardiovascular actions of neurotrophins, Physiol. Rev. 89
(2009) 279–308.
[45] G. Borland, B.O. Smith, S.J. Yarwood, EPAC proteins transduce diverse cellular actions
of cAMP, Br. J. Pharmacol. 158 (2009) 70–86.
[46] M. Breckler, M. Berthouze, A.C. Laurent, B. Crozatier, E. Morel, F. Lezoualc'h, Rap-
linked cAMP signaling Epac proteins: compartmentation, functioning and disease
implications, Cell. Signal. 23 (2011) 1257–1266.
[47] X. Cheng, Z. Ji, T. Tsalkova, F. Mei, Epac and PKA: a tale of two intracellular cAMP
receptors, Acta Biochim. Biophys. Sin. (Shanghai) 40 (2008) 651–662.
[48] M. Gloerich, J.L. Bos, Epac: deﬁning a new mechanism for cAMP action, Annu. Rev.
Pharmacol. Toxicol. 50 (2010) 355–375.
[49] M. Grandoch, S.S. Roscioni, M. Schmidt, The role of Epac proteins, novel cAMP
mediators, in the regulation of immune, lung and neuronal function, Br. J.
Pharmacol. 159 (2010) 265–284.
[50] P.A. Insel, L. Zhang, F. Murray, H. Yokouchi, A.C. Zambon, Cyclic AMP is both a pro-
apoptotic and anti-apoptotic second messenger, Acta Physiol. 204 (2011) 277–287.
[51] G.G. Holz, G. Kang, M. Harbeck, M.W. Roe, O.G. Chepurny, Cell physiology of cAMP
sensor Epac, J. Physiol. 577 (2006) 5–15.
[52] M.T. Branham, M.A. Bustos, G.A. De Blas, H. Rehmann, V.E. Zarelli, C.L. Trevino, A.
Darszon, L.S. Mayorga, C.N. Tomes, Epac activates the small G proteins Rap1 and
Rab3A to achieve exocytosis, J. Biol. Chem. 284 (2009) 24825–24839.
[53] W.R. Hartman, D.F. Smelter, V. Sathish, M. Karass, S. Kim, B. Aravamudan, M.A.
Thompson, Y. Amrani, H.C. Pandya, R.J. Martin, Y.S. Prakash, C.M. Pabelick, Oxygen
dose responsiveness of human fetal airway smooth muscle cells, Am. J. Physiol.
Lung Cell. Mol. Physiol. 303 (2012) L711–L719.
[54] R.D. Britt Jr., A. Faksh, E.R. Vogel, M.A. Thompson, V. Chu, H.C. Pandya, Y. Amrani, R.J.
Martin, C.M. Pabelick, Y.S. Prakash, Vitamin D attenuates cytokine-induced remodel-
ing in human fetal airway smooth muscle cells, J. Cell. Physiol. 230 (2014)
1189–1198.
[55] A.J. Abcejo, V. Sathish, D.F. Smelter, B. Aravamudan, M.A. Thompson, W.R. Hartman,
C.M. Pabelick, Y.S. Prakash, Brain-derived neurotrophic factor enhances calcium
regulatory mechanisms in human airway smooth muscle, PLoS One 7 (2012)
e44343.
[56] V. Sathish, S.K. Vanoosten, B.S. Miller, B. Aravamudan,M.A. Thompson, C.M. Pabelick,
R. Vassallo, Y.S. Prakash, Brain-derived neurotrophic factor in cigarette smoke-
induced airway hyperreactivity, Am. J. Respir. Cell Mol. Biol. 48 (2013) 431–438.
[57] P.K. Vohra, M.A. Thompson, V. Sathish, A. Kiel, C. Jerde, C.M. Pabelick, B.B. Singh, Y.S.
Prakash, TRPC3 regulates release of brain-derived neurotrophic factor from human
airway smooth muscle, Biochim. Biophys. Acta 1833 (2013) 2953–2960.
[58] T. Trian, J.K. Burgess, K. Niimi, L.M. Moir, Q. Ge, P. Berger, S.B. Liggett, J.L. Black, B.G.
Oliver, Beta2-agonist induced cAMP is decreased in asthmatic airway smooth
muscle due to increased PDE4D, PLoS One 6 (2011) e20000.
[59] V.P. Krymskaya, R.A. Panettieri Jr., Phosphodiesterases regulate airway smooth
muscle function in health and disease, Curr. Top. Dev. Biol. 79 (2007) 61–74.
[60] Y.P. de Visser, F.J. Walther, H. Laghmani el, P. Steendijk, M. Middeldorp, A. van der
Laarse, G.T. Wagenaar, Phosphodiesterase 4 inhibition attenuates persistent heart
and lung injury by neonatal hyperoxia in rats, Am. J. Physiol. Lung Cell. Mol. Physiol.
302 (2012) L56–L67.
[61] K. Woyda, S. Koebrich, I. Reiss, S. Rudloff, S.S. Pullamsetti, A. Ruhlmann, N.
Weissmann, H.A. Ghofrani, A. Gunther, W. Seeger, F. Grimminger, R.E. Morty, R.T.
2514 M.A. Thompson et al. / Biochimica et Biophysica Acta 1853 (2015) 2506–2514Schermuly, Inhibition of phosphodiesterase 4 enhances lung alveolarisation in
neonatal mice exposed to hyperoxia, Eur. Respir. J. 33 (2009) 861–870.
[62] A.M. Curatola, J. Xu, K.D. Hendricks-Munoz, Cyclic GMP protects endothelial
progenitors from oxidative stress, Angiogenesis 14 (2011) 267–279.
[63] W.Y. Yin F1, J.H. Du, C. Li, Z.Z. Lu, C. Han, Y.Y. Zhang, Noncanonical cAMP pathway
and p38 MAPK mediate beta2-adrenergic receptor-induced IL-6 production in
neonatal mouse cardiac ﬁbroblasts, J. Mol. Cell. Cardiol. 40 (2006) 384–393.
[64] M. Schmidt, F.J. Dekker, H. Maarsingh, Exchange protein directly activated by cAMP
(epac): a multidomain cAMP mediator in the regulation of diverse biological
functions, Pharmacol. Rev. 65 (2013) 670–709.
[65] C. Ulucan, X. Wang, E. Baljinnyam, Y. Bai, S. Okumura, M. Sato, S. Minamisawa, S.
Hirotani, Y. Ishikawa, Developmental changes in gene expression of Epac and its
upregulation in myocardial hypertrophy, Am. J. Physiol. Heart Circ. Physiol. 293
(2007) H1662–H1672.
[66] U. Yokoyama, H.H. Patel, N.C. Lai, N. Aroonsakool, D.M. Roth, P.A. Insel, The cyclic
AMP effector Epac integrates pro- and anti-ﬁbrotic signals, Proc. Natl. Acad.
Sci. U. S. A. 105 (2008) 6386–6391.
[67] T. Shibasaki, H. Takahashi, T. Miki, Y. Sunaga, K. Matsumura, M. Yamanaka, C. Zhang,
A. Tamamoto, T. Satoh, J. Miyazaki, S. Seino, Essential role of Epac2/Rap1 signaling in
regulation of insulin granule dynamics by cAMP, Proc. Natl. Acad. Sci. U. S. A. 104
(2007) 19333–19338.[68] S.S. Roscioni, L.E. Kistemaker, M.H. Menzen, C.R. Elzinga, R. Gosens, A.J. Halayko, H.
Meurs, M. Schmidt, PKA and Epac cooperate to augment bradykinin-induced
interleukin-8 release from human airway smooth muscle cells, Respir. Res. 10
(2009) 88.
[69] S.S. Roscioni, H. Maarsingh, C.R. Elzinga, J. Schuur, M.Menzen, A.J. Halayko, H. Meurs,
M. Schmidt, Epac as a novel effector of airway smooth muscle relaxation, J. Cell. Mol.
Med. 15 (2011) 1551–1563.
[70] S.J. Morgan, D.A. Deshpande, B.C. Tiegs, A.M. Misior, H. Yan, A.V. Hershfeld, T.C. Rich,
R.A. Panettieri, S.S. An, R.B. Penn, Beta-agonist-mediated relaxation of airway
smooth muscle is protein kinase A-dependent, J. Biol. Chem. 289 (2014)
23065–23074.
[71] D. Willoughby, W. Wong, J. Schaack, J.D. Scott, D.M. Cooper, An anchored PKA and
PDE4 complex regulates subplasmalemmal cAMP dynamics, Embo J. 25 (2006)
2051–2061.
[72] S.J. Horvat, D.A. Deshpande, H. Yan, R.A. Panettieri, J. Codina, T.D. DuBose Jr., W. Xin,
T.C. Rich, R.B. Penn, A-kinase anchoring proteins regulate compartmentalized cAMP
signaling in airway smooth muscle, Faseb J. 26 (2012) 3670–3679.
[73] K.L. Dodge-Kafka, J. Soughayer, G.C. Pare, J.J. Carlisle Michel, L.K. Langeberg, M.S.
Kapiloff, J.D. Scott, The protein kinase A anchoring protein mAKAP coordinates
two integrated cAMP effector pathways, Nature 437 (2005) 574–578.
